- Home
- OMC vs GMAB Comparison
OMC vs GMAB Comparison
Compare OMC & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMC
- GMAB
- Stock Information
- Founded
- OMC 1944
- GMAB 1999
- Country
- OMC United States
- GMAB Denmark
- Employees
- OMC N/A
- GMAB N/A
- Industry
- OMC Advertising
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- OMC Consumer Discretionary
- GMAB Health Care
- Exchange
- OMC Nasdaq
- GMAB Nasdaq
- Market Cap
- OMC 14.0B
- GMAB 15.4B
- IPO Year
- OMC N/A
- GMAB N/A
- Fundamental
- Price
- OMC $78.36
- GMAB $24.87
- Analyst Decision
- OMC Buy
- GMAB Buy
- Analyst Count
- OMC 7
- GMAB 6
- Target Price
- OMC $94.43
- GMAB $37.60
- AVG Volume (30 Days)
- OMC 3.4M
- GMAB 1.3M
- Earning Date
- OMC 10-14-2025
- GMAB 08-07-2025
- Dividend Yield
- OMC 3.57%
- GMAB N/A
- EPS Growth
- OMC N/A
- GMAB 77.72
- EPS
- OMC 7.00
- GMAB 21.62
- Revenue
- OMC $15,910,800,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- OMC $4.79
- GMAB $22.68
- Revenue Next Year
- OMC $9.15
- GMAB $15.85
- P/E Ratio
- OMC $11.20
- GMAB $11.17
- Revenue Growth
- OMC 5.21
- GMAB 32.97
- 52 Week Low
- OMC $68.37
- GMAB $17.24
- 52 Week High
- OMC $107.00
- GMAB $27.93
- Technical
- Relative Strength Index (RSI)
- OMC 59.80
- GMAB 65.71
- Support Level
- OMC $77.03
- GMAB $24.28
- Resistance Level
- OMC $78.78
- GMAB $25.25
- Average True Range (ATR)
- OMC 1.49
- GMAB 0.37
- MACD
- OMC 0.17
- GMAB 0.16
- Stochastic Oscillator
- OMC 77.50
- GMAB 90.69
About OMC Omnicom Group Inc.
Omnicom is a holding company that owns several advertising agencies and related firms. It provides traditional and digital advertising services that include creative design, market research, data analytics, and ad placement. In addition, Omnicom provides outsourced public relations and other communications services. The firm operates globally, providing services in more than 70 countries; it generates more than half of its revenue in North America and nearly 30% in Europe. The firm announced plans to merge with Interpublic Group in December 2024, pending regulatory approval.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.